RIPK2-IN-1
CAS No. 1423186-80-4
RIPK2-IN-1( GSK2983559 | GSK-2983559 | GSK 2983559 | RIPK2-IN-1 | RIPK2 IN 1 )
Catalog No. M11784 CAS No. 1423186-80-4
A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 87 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 259 | In Stock |
|
| 50MG | 484 | In Stock |
|
| 100MG | 700 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRIPK2-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.
-
DescriptionA potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.(In Vitro):GSK2983559 active metabolite is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region. The CARD domain of RIP2 kinase mediates interaction with other CARD-containing proteins, such as NODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide.
-
In VitroGSK2983559 active metabolite is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region. The CARD domain of RIP2 kinase mediates interaction with other CARD-containing proteins, such as NODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide.
-
In Vivo——
-
SynonymsGSK2983559 | GSK-2983559 | GSK 2983559 | RIPK2-IN-1 | RIPK2 IN 1
-
PathwayApoptosis
-
TargetRIP kinase
-
RecptorRIP2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1423186-80-4
-
Formula Weight458.5538
-
Molecular FormulaC21H22N4O4S2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=S(C1=CC2=C(NC3=CC=C(SC=N4)C4=C3)N=CN=C2C=C1OCCO)(C(C)(C)C)=O
-
Chemical NameEthanol, 2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Linda N. Casillas, et al. Prodrugs of amino quinazoline kinase inhibitor. PCT Int. Appl. (2014), WO 2014043446 A1 20140320.
molnova catalog
related products
-
GSK547
GSK547 (RIP1i, GSK 547) is a highly selective and potent inhibitor of RIP1 kinase that robustly targets RIP1 in vivo.
-
RIPK1-IN-4
RIPK1-IN-4 is a potent and selective type II kinase receptor interacting protein 1 (RIP1) kinase inhibitor and binds to a DLG-out inactive form of RIP1 (IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase).
-
Sibiriline
A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3.
Cart
sales@molnova.com